- Company
- Export of Celltrion/Samsung bioepis exceed ₩10trillion
- by Chon, Seung-Hyun Apr 3, 2022 04:18pm
- According to the Financial Supervisory Service on the 1st, four biosimilars, Celltrion Healthcare's Remsima, Truxima, Herzuma and Remsima SC, recorded a total of 1.5694 trillion won in exports last year. It fell 2.0% from 1.616 trillion won in 2020, but exceeded 1 trillion won for the third consecutive year from 2019. Celltrion Healthcare is an
- Company
- MS anticancer drug Revlimid, RVD combined therapy benefits
- by Nho, Byung Chul Apr 3, 2022 04:13pm
- BMS Pharmaceutical Korea announced on the 30th that Revlimid (Renalidomide) will be subject to benefits when administered in combination with Bortezomib/Dexamethasone, which is used to treat multiple myeloma patients, from the 1st of next month. The law has proven its superior effectiveness and tolerance compared to current standard treatm
- Company
- Revlimid's reimb extended…maintenance therapy remains
- by Eo, Yun-Ho Apr 1, 2022 06:04am
- The reimbursement standards for ‘Revlimid’ in combination with Velcade, and dexamethasone (RVD) for multiple myeloma have been extended. However, reimbursement for the drug as a maintenance therapy still remains unaddressed. Starting on April 1st, BMS Korea’s Revlimid (lenalidomide) will receive insurance benefits as part of RVd (lenal
- Company
- Roche joins in competition for RET-targeted therapies
- by Apr 1, 2022 06:03am
- Following Lilly, Roche has also received approval for its RET targeted anticancer therapy. The entrance of two drugs in a similar period is expected to spark new competition in the RET-targeted therapy market. On the 29th, Roche received marketing authorization for ‘Gavreto (pralsetinib) from the Ministry of Food and Drug Safety. Its fir
- Policy
- The MFDS released a national lot release of Comirnaty
- by Lee, Hye-Kyung Mar 31, 2022 04:29pm
- The MFDS (Director Kim Kang-rip) announced on the 29th that it has released 299,000 doses of Pfizer's Comirnaty 0.1mg/mL (for 5-11 years old) in Korea. The MFDS conducted Comirnaty test and reviewed the manufacturing and test data of the manufacturer, and confirmed the effectiveness, safety, and quality, and decided to release the national
- Company
- Sandoz, launched a muscle relaxation antagonist with Ilsung
- by Mar 31, 2022 04:27pm
- Sandoz Korea announced on the 29th that it signed an exclusive sales partnership with Ilsung on the 28th with muscle relaxation antagonist Sandoz Sugammedex Sodium. According to the agreement, the two companies will start supplying and selling Sandoz Sugamadex on the 13th of next month. The two companies expected that Ilsung's sales know-how,
- Policy
- Roche RET target anticancer drug Gavreto, approved in Korea
- by Lee, Hye-Kyung Mar 31, 2022 04:23pm
- Roche's non-small cell lung cancer treatment Gavreto (Pralsetinib)"has obtained an item license in Korea. The MFDS approved Gavreto 100mg on the 29th. The drug was recognized for its effectiveness in the treatment of ▲RET (RET) fusion-positive local progression or metastatic non-small cell lung cancer adult patients and ▲ systemic therap
- Company
- First-ever RET inhibitor 'Retevmo' attempts reimbursement
- by Eo, Yun-Ho Mar 31, 2022 05:58am
- The first RET-targeted anticancer therapy is attempting to receive insurance reimbursement in Korea. According to industry sources, Lilly Korea has recently submitted a reimbursement application for its ‘Retevmo (selpercatinib) that targets the RET (Rearranged during transfection)-gene fusions. After receiving approval from the Ministry
- Policy
- Reimbursement priorities in ultra-high-priced one-shot Txs
- by Lee, Tak-Sun Mar 31, 2022 05:57am
- With the reimbursement imminent for the ultra-high-priced one-shot treatment Kymriah, the National Health Insurance Service is preparing to conduct research on the performance evaluation of the risk-sharing agreement (RSA) and its mid-to-long-term development direction. The research will be exploring ways on the development direction of
- Company
- Kidney care is also important for diabetic patients
- by Eo, Yun-Ho Mar 30, 2022 06:09am
- SGLT-2 inhibitors, which have obtained indications for chronic kidney disease, are emerging as the mainstay of chronic disease management along with diabetes. According to data from the Korean Diabetes Association, the rate of kidney disease accompanied by type 2 diabetes patients in Korea was about 30%, and one in three diabetes patients in
